- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: What the Generics Industry Can Tell Us About the Future of Biosimilars
On this week’s episode of Not So Different, we spoke with David Senior, senior vice president of Market Economics at AmerisourceBergen, about the development of the generics market and how this could be instructive in understanding how biosimilars sales may develop.
On this week’s episode, we sat down with David Senior, senior vice president of Market Economics at AmerisourceBergen. We discussed how the generics market developed in the United States and some of the challenges that it faced. We also talked about how the US generics industry could be instructive in understanding how biosimilar sales may develop over time.
To learn more about the Hatch-Waxman Act, click here.
To learn more about how biosimilars compare with the generics market, click here.
To learn more about the challenges that both the biosimilars and generic markets face, click here.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Escaping the Void: All Things Biosimilars With Craig & G
August 2nd 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
